New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
07:17 EDTOMEROmeros announces data using OMS721 in patients with aHUS
Omeros Corporation announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome, a form of thrombotic microangiopathy. In February, Omeros reported positive results from its OMS721 Phase 1 clinical trial and, earlier this month, announced submission of an investigational new drug application to the U.S. Food and Drug Administration to initiate a Phase 2 clinical trial in patients with TMA, including patients with aHUS. The data announced resulted from studies conducted in support of the clinical evaluation of OMS721 by Prof. Giuseppe Remuzzi and colleagues Marina Noris and Miriam Galbusera at the Mario Negri Institute for Pharmacological Research in Bergamo, Italy, and the Clinical Research Center for Rare Diseases "Aldo e Cele Daccò" of the same Institute, a European center for collecting and studying TMA samples.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 29, 2015
09:06 EDTOMEROn The Fly: Pre-market Movers
UP AFTER EARNINGS: Flextronics (FLEX), up 6%... Coach (COH), up 6.3%... Autoliv (ALV), up 4.3%... Dow Chemical (DOW), up 3.5%... Ford (F), up 0.8%. ALSO HIGHER: McDonald's (MCD), up 3% after announcing CEO change...Xencor (XNCR), up 19% after reporting results from two trials... Pluristem Therapeutics (PSTI), up 8% after providing update and outlook on trials and pipeline... Avon Products (AVP), up 2.3% after naming James Scully as CFO... Omeros (OMER), up 6% after 2.996M share spot secondary priced at $20.03. DOWN AFTER EARNINGS: Alibaba (BABA), down 8%... Qualcomm (QCOM), down 6.8%... Alexion (ALXN), down 1.1% after reporting fourth quarter results, fiscal 2015 guidance, and CEO appointment. ALSO LOWER: Yahoo (YHOO), down 7% following Alibaba earnings report... Venaxis (APPY), down 72% after its APPY1 Test was determined by the FDA to not meet the criteria for substantial equivalence.
08:35 EDTOMEROmeros 2.996M share Spot Secondary priced at $20.03
Subscribe for More Information
January 28, 2015
16:03 EDTOMEROmeros files to sell common stock and pre-funded warrants
Omeros intends to offers shares of its common stock and pre-funded warrants to purchase shares of its common stock in a registered underwritten public offering. The pre-funded warrants shall be offered at the same price per share as the common stock, less the $0.01 per share exercise price of each pre-funded warrant. Cowen and Company, LLC is acting as the sole book-running manager for the offering.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use